Skip to main content

Advertisement

Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Aberrant activation of CYR61 enhancers in colorectal cancer development

Fig. 5

Small molecule compounds regulate CYR61 expression through affecting enhancer activity. a-d TPA treatment. a CYR61 protein, and b CYR61 mRNA and eRNA levels after treatment of NCM460, HCT116, and RKO cells with TPA for 2 h. (C) H3K4me3, H3K4me1, H3K27ac, and CBP enrichment after treatment with 100 ng/ml TPA for 2 h in HCT116 cells, as assessed by ChIP-qPCR. d Relative crosslinking frequencies of CYR61 promoter/Enhancer3 were increased after treatment with 100 ng/ml of TPA for 2 h in HCT116 cells, as assessed by 3C, significance determined by paired-samples t-test. e, h VP treatment. e CYR61 protein, and f CYR61 mRNA and eRNA levels after treatment of RKO and HCT116 cells with VP for 2 h. g H3K4me3, H3K4me1, H3K27ac and CBP enrichment after treatment with 10 μg/ml VP for 1 or 2 h in RKO cells, as assessed by ChIP-qPCR. h Relative crosslinking frequencies of the CYR61 promoter/Enhancer1 and CYR61 promoter/Enhancer3 were decreased after treatment of RKO cells with 10 μg/ml VP for 1 h, as assessed by 3C; significance determined by the paired-samples t-test. Significance for all data except d and h was determined by the independent samples t-test. Data are shown as mean ± S.D., n = 3. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page